Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.
Coronavirus disease 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still a pandemic around the world. Currently, specific antiviral drugs to control the epidemic remain deficient. Understanding the details of SARS-CoV-2 structural biology is extremely important for development of antiviral agents that will enable regulation of its life cycle. This review focuses on the structural biology and medicinal chemistry of various key proteins (Spike, ACE2, TMPRSS2, RdRp and Mpro) in the life cycle of SARS-CoV-2, as well as their inhibitors/drug candidates. Representative broad-spectrum antiviral drugs, especially those against the homologous virus SARS-CoV, are summarized with the expectation they will drive the development of effective, broad-spectrum inhibitors against coronaviruses. We are hopeful that this review will be a useful aid for discovery of novel, potent anti-SARS-CoV-2 drugs with excellent therapeutic results in the near future.
['Zhuo|Lin-Sheng|LS|', 'Wang|Ming-Shu|MS|', 'Yang|Jing-Fang|JF|', 'Xu|Hong-Chuang|HC|', 'Huang|Wei|W|', 'Shang|Lu-Qing|LQ|', 'Yang|Guang-Fu|GF|http://orcid.org/0000-0003-4384-2593']
D000085962:Angiotensin-Converting Enzyme 2 D000998:Antiviral Agents D000086382:COVID-19 D058492:Drug Repositioning D006801:Humans D000086402:SARS-CoV-2 D012697:Serine Endopeptidases D064370:Spike Glycoprotein, Coronavirus D014763:Viral Matrix Proteins D053586:Virus Internalization
SARS-CoV-2 Antiviral Structural biology COVID-19 Drug discovery